Truist Securities Initiates Coverage On Antares Pharma with Buy Rating, Announces Price Target of $7
Truist Securities analyst Gregg Gilbert initiates coverage on Antares Pharma (NASDAQ:ATRS) with a Buy rating and announces Price Target of $7.
Idorsia Initiates the Phase 3 Registration Study With Selatogrel Using Antares’ Autoinjector for the Treatment of Acute Myocardial Infarction
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell
• ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.